The prevalence of JAK2 exon12 mutations in Vietnamese patients with JAK2 V617F-negative polycythemia vera: frequent or rare?

被引:0
|
作者
Nguyen Thy Ngoca [1 ]
Nguyen Thuy Linh [1 ]
Nguyen Thi Xuan [2 ]
机构
[1] Univ Sci & Technol Hanoi, Vietnam Acad Sci & Technol, Hanoi, Vietnam
[2] Vietnam Acad Sci & Technol, Inst Genome Res, Hanoi, Vietnam
关键词
MYELOPROLIFERATIVE NEOPLASMS; TET2; TOOL;
D O I
10.1159/000526201
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
PurposePolycythemia vera is a hematological malignancy characterized by the overproduction of red blood cells in the bone marrow. Pathogenesis of Polycythemia vera was thought to be caused by genetic mutations of the Janus kinase 2 (JAK2) gene, especially the JAK2 V617F and exon 12 mutations since those mutations were found frequently in the patients. The prevalence of JAK2 exon 12 mutations among Polycythemia Vera patients in Vietnam has not been studied yet.ObjectivesThe overall study objective is to investigate the frequency of JAK2 exon 12 mutations among V617F-negative Polycythemia Vera patients in Vietnam. MethodsIn this study, the occurrence of these mutations was investigated in a clinical population of 76 Vietnamese Polycythemia Vera patients by PCR-RFLP and Sanger sequencing. ResultsThe result showed that 53 of the patients were V617F-positive, and in 23 V617F-negative patients, only four individuals carried two JAK2 exon 12 mutations. Analysis by different in-silico tools predicted that all the two exon 12 mutations detected in this study (JAK2 c.1592A>G; p.H531R and c.1616A>G p.K539R) were benign.ConclusionThese results suggested that the causative mutations in this V617F-negative subgroup might locate in another genetic region, and mutations in exon 12 might not be as common among the V617F-negative Polycythemia Vera patients as thought.
引用
收藏
页码:102 / 106
页数:5
相关论文
共 50 条
  • [1] JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis
    Maddali, Madhavi
    Kulkarni, Uday Prakash
    Ravindra, Niveditha
    Jajodia, Ekta
    Arunachalam, Arun Kumar
    Suresh, Hemamalini
    Venkatraman, Arvind
    George, Biju
    Mathews, Vikram
    Balasubramanian, Poonkuzhali
    ANNALS OF HEMATOLOGY, 2020, 99 (05) : 983 - 989
  • [2] Coexistence of gain-of-function JAK2 germ line mutations with JAK2V617F in polycythemia vera
    Lanikova, Lucie
    Babosova, Olga
    Swierczek, Sabina
    Wang, Linghua
    Wheeler, David A.
    Divoky, Vladimir
    Korinek, Vladimir
    Prchal, Josef T.
    BLOOD, 2016, 128 (18) : 2266 - +
  • [3] Bone Marrow Morphologic Features in Polycythemia Vera With JAK2 Exon 12 Mutations
    Lakey, Meredith A.
    Pardanani, Animesh
    Hoyer, James D.
    Nguyen, Phuong L.
    Lasho, Terra L.
    Tefferi, Ayalew
    Hanson, Curtis A.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2010, 133 (06) : 942 - 948
  • [4] The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera
    Olcaydu, D.
    Skoda, R. C.
    Looser, R.
    Li, S.
    Cazzola, M.
    Pietra, D.
    Passamonti, F.
    Lippert, E.
    Carillo, S.
    Girodon, F.
    Vannucchi, A.
    Reading, N. S.
    Prchal, J. T.
    Ay, C.
    Pabinger, I.
    Gisslinger, H.
    Kralovics, R.
    LEUKEMIA, 2009, 23 (10) : 1924 - 1926
  • [5] Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
    Lee, A-Jin
    Kim, Sang-Gyung
    Nam, Jun Yeb
    Yun, Jaehum
    Ryoo, Hun-Mo
    Bae, Sung Hwa
    BLOOD RESEARCH, 2021, 56 (04) : 259 - 265
  • [6] CALR, JAK2 Exon 14, and JAK2 Exon 12 mutations profiles in patients with Myeloproliferative Neoplasms
    Yasin, Elrashed B.
    Alkhatabi, Heba
    Ahmedah, Hanadi Talal
    Felimban, Raed
    Tayeb, Hossam H.
    Alalla, Zainab Jawdat
    Abdulqayoom, Heyam Abdulsamad
    Alserihi, Raed
    BIOSCIENCE RESEARCH, 2021, 18 (02): : 1699 - 1707
  • [7] JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease
    Tefferi, Ayalew
    Lavu, Sravanthi
    Mudireddy, Mythri
    Lasho, Terra L.
    Finke, Christy M.
    Gangat, Naseema
    Pardanani, Animesh
    Hanson, Curtis A.
    Mannarelli, Carmela
    Guglielmelli, Paola
    Vannucchi, Alessandro M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (04) : E93 - E96
  • [8] Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F
    Stein, Brady L.
    Oh, Stephen T.
    Berenzon, Dmitriy
    Hobbs, Gabriela S.
    Kremyanskaya, Marina
    Rampal, Raajit K.
    Abboud, Camille N.
    Adler, Kenneth
    Heaney, Mark L.
    Jabbour, Elias J.
    Komrokji, Rami S.
    Moliterno, Alison R.
    Ritchie, Ellen K.
    Rice, Lawrence
    Mascarenhas, John
    Hoffman, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (33) : 3953 - +
  • [9] Diagnosis and therapy of polycythemia vera in the era of JAK2
    Lengfelder, E.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2013, 138 (07) : 331 - 336
  • [10] Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population
    Cordua, Sabrina
    Kjaer, Lasse
    Skov, Vibe
    Pallisgaard, Niels
    Hasselbalch, Hans C.
    Ellervik, Christina
    BLOOD, 2019, 134 (05) : 469 - 479